Precisis is a neurotechnology company developing implantable neuromodulation therapies for patients with drug-resistant focal epilepsy. The company focuses on offering a less invasive alternative to traditional epilepsy surgery by electrically modulating seizure-generating brain regions.

Its core technology, the EASEE® system, delivers focal electrical stimulation via thin, minimally invasive electrodes placed directly at epileptogenic zones. The system is designed to reduce seizure frequency while preserving surrounding brain tissue and minimizing surgical burden compared with resective approaches.

Precisis’s technology is intended for clinical use in epilepsy centers as a therapeutic option for patients who are not candidates for conventional surgery. The company positions its platform as a targeted neuromodulation therapy that bridges the gap between medication and invasive surgical intervention.